Ocugen (FRA:2H51) Short-Term Debt : €1.19 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ocugen Short-Term Debt?

Ocugen's Short-Term Debt for the quarter that ended in Mar. 2024 was €1.19 Mil.

Ocugen's quarterly Short-Term Debt declined from Sep. 2023 (€1.20 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€1.19 Mil).

Ocugen Short-Term Debt Historical Data

The historical data trend for Ocugen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Short-Term Debt Chart

Ocugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

0.19

Ocugen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															1.17	1.17	1.20	-	1.19

Ocugen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ocugen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Ocugen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen (FRA:2H51) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

OCGN:USA OCGN:Mexico

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines